nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK14—coronary artery disease	0.143	0.428	CbGaD
Nilotinib—TEK—coronary artery disease	0.131	0.392	CbGaD
Nilotinib—KIT—coronary artery disease	0.0603	0.18	CbGaD
Nilotinib—CA14—Furosemide—coronary artery disease	0.0174	0.0488	CbGbCtD
Nilotinib—CA6—Furosemide—coronary artery disease	0.0166	0.0463	CbGbCtD
Nilotinib—CA7—Furosemide—coronary artery disease	0.0144	0.0404	CbGbCtD
Nilotinib—CA12—Furosemide—coronary artery disease	0.0124	0.0347	CbGbCtD
Nilotinib—CA9—Furosemide—coronary artery disease	0.0124	0.0347	CbGbCtD
Nilotinib—CA1—Furosemide—coronary artery disease	0.0116	0.0324	CbGbCtD
Nilotinib—UGT1A1—Ezetimibe—coronary artery disease	0.0112	0.0313	CbGbCtD
Nilotinib—CA4—Furosemide—coronary artery disease	0.0109	0.0305	CbGbCtD
Nilotinib—UGT1A1—Simvastatin—coronary artery disease	0.0104	0.0291	CbGbCtD
Nilotinib—UGT1A1—Lovastatin—coronary artery disease	0.0102	0.0285	CbGbCtD
Nilotinib—CA2—Furosemide—coronary artery disease	0.01	0.028	CbGbCtD
Nilotinib—UGT1A1—Atorvastatin—coronary artery disease	0.00928	0.0259	CbGbCtD
Nilotinib—UGT1A1—Losartan—coronary artery disease	0.00848	0.0237	CbGbCtD
Nilotinib—ABCG2—Telmisartan—coronary artery disease	0.00835	0.0234	CbGbCtD
Nilotinib—ABCG2—Pitavastatin—coronary artery disease	0.00835	0.0234	CbGbCtD
Nilotinib—CYP2C8—Fenofibrate—coronary artery disease	0.00734	0.0205	CbGbCtD
Nilotinib—CYP2B6—Clopidogrel—coronary artery disease	0.00672	0.0188	CbGbCtD
Nilotinib—ABCG2—Rosuvastatin—coronary artery disease	0.00616	0.0172	CbGbCtD
Nilotinib—ABCG2—Ezetimibe—coronary artery disease	0.00616	0.0172	CbGbCtD
Nilotinib—CYP2C8—Gemfibrozil—coronary artery disease	0.00587	0.0164	CbGbCtD
Nilotinib—ABCG2—Pravastatin—coronary artery disease	0.0056	0.0157	CbGbCtD
Nilotinib—ABCB1—Ticagrelor—coronary artery disease	0.00558	0.0156	CbGbCtD
Nilotinib—CYP2C9—Fenofibrate—coronary artery disease	0.00512	0.0143	CbGbCtD
Nilotinib—CYP2C8—Clopidogrel—coronary artery disease	0.00509	0.0142	CbGbCtD
Nilotinib—CYP2C8—Pitavastatin—coronary artery disease	0.00445	0.0124	CbGbCtD
Nilotinib—CYP2C9—Gemfibrozil—coronary artery disease	0.00409	0.0115	CbGbCtD
Nilotinib—CYP2B6—Simvastatin—coronary artery disease	0.00403	0.0113	CbGbCtD
Nilotinib—CYP2B6—Atorvastatin—coronary artery disease	0.00359	0.01	CbGbCtD
Nilotinib—CYP2C9—Clopidogrel—coronary artery disease	0.00355	0.00993	CbGbCtD
Nilotinib—ABCB1—Perindopril—coronary artery disease	0.00345	0.00964	CbGbCtD
Nilotinib—ABCB1—Clopidogrel—coronary artery disease	0.00345	0.00964	CbGbCtD
Nilotinib—CYP3A4—Ticagrelor—coronary artery disease	0.00334	0.00934	CbGbCtD
Nilotinib—CYP2C8—Acetylsalicylic acid—coronary artery disease	0.0032	0.00894	CbGbCtD
Nilotinib—CYP2C9—Pitavastatin—coronary artery disease	0.0031	0.00868	CbGbCtD
Nilotinib—CYP2C8—Simvastatin—coronary artery disease	0.00305	0.00853	CbGbCtD
Nilotinib—CYP2C9—Valsartan—coronary artery disease	0.00302	0.00844	CbGbCtD
Nilotinib—ABCB1—Pitavastatin—coronary artery disease	0.00301	0.00842	CbGbCtD
Nilotinib—ABCB1—Telmisartan—coronary artery disease	0.00301	0.00842	CbGbCtD
Nilotinib—CYP2C8—Pravastatin—coronary artery disease	0.00298	0.00835	CbGbCtD
Nilotinib—CYP2C8—Lovastatin—coronary artery disease	0.00298	0.00835	CbGbCtD
Nilotinib—CYP3A4—Fenofibrate—coronary artery disease	0.00298	0.00833	CbGbCtD
Nilotinib—ABCB1—Enalapril—coronary artery disease	0.00285	0.00798	CbGbCtD
Nilotinib—ABCB1—Lisinopril—coronary artery disease	0.00285	0.00798	CbGbCtD
Nilotinib—CYP2C8—Atorvastatin—coronary artery disease	0.00272	0.0076	CbGbCtD
Nilotinib—CYP2C8—Losartan—coronary artery disease	0.00249	0.00695	CbGbCtD
Nilotinib—CYP2D6—Niacin—coronary artery disease	0.00246	0.00688	CbGbCtD
Nilotinib—ABCB1—Timolol—coronary artery disease	0.00243	0.00679	CbGbCtD
Nilotinib—CYP3A4—Gemfibrozil—coronary artery disease	0.00238	0.00666	CbGbCtD
Nilotinib—CYP2C9—Rosuvastatin—coronary artery disease	0.00229	0.0064	CbGbCtD
Nilotinib—CYP2D6—Timolol—coronary artery disease	0.00229	0.0064	CbGbCtD
Nilotinib—CYP2C9—Acetylsalicylic acid—coronary artery disease	0.00223	0.00623	CbGbCtD
Nilotinib—ABCB1—Ezetimibe—coronary artery disease	0.00222	0.00621	CbGbCtD
Nilotinib—CA3—pericardium—coronary artery disease	0.0022	0.0476	CbGeAlD
Nilotinib—EPHA2—pulmonary artery—coronary artery disease	0.00216	0.0468	CbGeAlD
Nilotinib—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00216	0.00605	CbGbCtD
Nilotinib—ABCB1—Captopril—coronary artery disease	0.00214	0.00598	CbGbCtD
Nilotinib—CYP2C9—Simvastatin—coronary artery disease	0.00213	0.00595	CbGbCtD
Nilotinib—CYP2C9—Pravastatin—coronary artery disease	0.00208	0.00582	CbGbCtD
Nilotinib—CYP2C9—Lovastatin—coronary artery disease	0.00208	0.00582	CbGbCtD
Nilotinib—CYP3A4—Clopidogrel—coronary artery disease	0.00206	0.00577	CbGbCtD
Nilotinib—ABCB1—Simvastatin—coronary artery disease	0.00206	0.00577	CbGbCtD
Nilotinib—ABCB1—Pravastatin—coronary artery disease	0.00202	0.00565	CbGbCtD
Nilotinib—ABCB1—Lovastatin—coronary artery disease	0.00202	0.00565	CbGbCtD
Nilotinib—CYP2D6—Captopril—coronary artery disease	0.00201	0.00563	CbGbCtD
Nilotinib—CYP2D6—Simvastatin—coronary artery disease	0.00194	0.00544	CbGbCtD
Nilotinib—CYP3A4—Eplerenone—coronary artery disease	0.00192	0.00537	CbGbCtD
Nilotinib—CYP2D6—Lovastatin—coronary artery disease	0.0019	0.00532	CbGbCtD
Nilotinib—CYP2D6—Pravastatin—coronary artery disease	0.0019	0.00532	CbGbCtD
Nilotinib—CYP2C9—Atorvastatin—coronary artery disease	0.0019	0.0053	CbGbCtD
Nilotinib—CYP2C9—cardial valve—coronary artery disease	0.00189	0.0409	CbGeAlD
Nilotinib—ABCB1—Atorvastatin—coronary artery disease	0.00184	0.00514	CbGbCtD
Nilotinib—CYP2C9—Losartan—coronary artery disease	0.00173	0.00485	CbGbCtD
Nilotinib—CYP2D6—Atorvastatin—coronary artery disease	0.00173	0.00485	CbGbCtD
Nilotinib—CYP3A4—Enalapril—coronary artery disease	0.00171	0.00478	CbGbCtD
Nilotinib—ABCB1—Losartan—coronary artery disease	0.00168	0.00471	CbGbCtD
Nilotinib—MAPK8—artery—coronary artery disease	0.00136	0.0294	CbGeAlD
Nilotinib—CYP3A4—Rosuvastatin—coronary artery disease	0.00133	0.00372	CbGbCtD
Nilotinib—CYP3A4—Ezetimibe—coronary artery disease	0.00133	0.00372	CbGbCtD
Nilotinib—CYP3A4—Simvastatin—coronary artery disease	0.00124	0.00346	CbGbCtD
Nilotinib—CYP3A4—Lovastatin—coronary artery disease	0.00121	0.00338	CbGbCtD
Nilotinib—CYP3A4—Pravastatin—coronary artery disease	0.00121	0.00338	CbGbCtD
Nilotinib—MAPK8—endothelium—coronary artery disease	0.00115	0.0248	CbGeAlD
Nilotinib—Ponatinib—TEK—coronary artery disease	0.0011	0.412	CrCbGaD
Nilotinib—CYP3A4—Atorvastatin—coronary artery disease	0.0011	0.00308	CbGbCtD
Nilotinib—CYP3A4—Losartan—coronary artery disease	0.00101	0.00282	CbGbCtD
Nilotinib—TIE1—endothelium—coronary artery disease	0.000995	0.0215	CbGeAlD
Nilotinib—CDC42BPB—cardiac ventricle—coronary artery disease	0.000842	0.0182	CbGeAlD
Nilotinib—TEK—artery—coronary artery disease	0.000783	0.0169	CbGeAlD
Nilotinib—MAPK8—myocardium—coronary artery disease	0.000717	0.0155	CbGeAlD
Nilotinib—EPHB4—endothelium—coronary artery disease	0.000691	0.0149	CbGeAlD
Nilotinib—TEK—endothelium—coronary artery disease	0.000661	0.0143	CbGeAlD
Nilotinib—TIE1—myocardium—coronary artery disease	0.000621	0.0134	CbGeAlD
Nilotinib—MAPK11—heart—coronary artery disease	0.000558	0.0121	CbGeAlD
Nilotinib—CDC42BPB—heart—coronary artery disease	0.000553	0.012	CbGeAlD
Nilotinib—HCK—myocardium—coronary artery disease	0.000543	0.0117	CbGeAlD
Nilotinib—Ponatinib—KDR—coronary artery disease	0.000539	0.201	CrCbGaD
Nilotinib—EPHA3—heart—coronary artery disease	0.000524	0.0113	CbGeAlD
Nilotinib—CDC42BPB—cardiovascular system—coronary artery disease	0.000522	0.0113	CbGeAlD
Nilotinib—CA3—cardiac ventricle—coronary artery disease	0.000518	0.0112	CbGeAlD
Nilotinib—Ponatinib—KIT—coronary artery disease	0.000509	0.19	CrCbGaD
Nilotinib—MAPK8—heart—coronary artery disease	0.0005	0.0108	CbGeAlD
Nilotinib—EPHA4—myocardium—coronary artery disease	0.000494	0.0107	CbGeAlD
Nilotinib—CA3—myocardium—coronary artery disease	0.000488	0.0105	CbGeAlD
Nilotinib—KIT—endothelium—coronary artery disease	0.000479	0.0103	CbGeAlD
Nilotinib—CDC42BPB—cardiac atrium—coronary artery disease	0.000473	0.0102	CbGeAlD
Nilotinib—BLK—blood—coronary artery disease	0.000472	0.0102	CbGeAlD
Nilotinib—MAPK8—cardiovascular system—coronary artery disease	0.000472	0.0102	CbGeAlD
Nilotinib—CA14—cardiac ventricle—coronary artery disease	0.000471	0.0102	CbGeAlD
Nilotinib—EPHB4—cardiac ventricle—coronary artery disease	0.000459	0.00991	CbGeAlD
Nilotinib—MAP4K1—heart—coronary artery disease	0.000455	0.00983	CbGeAlD
Nilotinib—TEK—cardiac ventricle—coronary artery disease	0.000439	0.00949	CbGeAlD
Nilotinib—TIE1—heart—coronary artery disease	0.000434	0.00937	CbGeAlD
Nilotinib—EPHB4—myocardium—coronary artery disease	0.000431	0.00933	CbGeAlD
Nilotinib—BRAF—heart—coronary artery disease	0.000416	0.00899	CbGeAlD
Nilotinib—TEK—myocardium—coronary artery disease	0.000413	0.00892	CbGeAlD
Nilotinib—EPHB3—heart—coronary artery disease	0.000412	0.00892	CbGeAlD
Nilotinib—TIE1—cardiovascular system—coronary artery disease	0.000409	0.00885	CbGeAlD
Nilotinib—HCK—heart—coronary artery disease	0.000379	0.00819	CbGeAlD
Nilotinib—ABL2—heart—coronary artery disease	0.000377	0.00814	CbGeAlD
Nilotinib—MAPK8—blood—coronary artery disease	0.000373	0.00807	CbGeAlD
Nilotinib—TIE1—cardiac atrium—coronary artery disease	0.000371	0.00802	CbGeAlD
Nilotinib—EPHA4—heart—coronary artery disease	0.000345	0.00745	CbGeAlD
Nilotinib—LYN—blood—coronary artery disease	0.000344	0.00745	CbGeAlD
Nilotinib—CA3—heart—coronary artery disease	0.00034	0.00736	CbGeAlD
Nilotinib—MAP4K1—blood—coronary artery disease	0.000339	0.00733	CbGeAlD
Nilotinib—MAP2K5—myocardium—coronary artery disease	0.000337	0.00729	CbGeAlD
Nilotinib—CA3—cardiovascular system—coronary artery disease	0.000321	0.00694	CbGeAlD
Nilotinib—MAPK14—heart—coronary artery disease	0.000318	0.00687	CbGeAlD
Nilotinib—FGR—heart—coronary artery disease	0.000316	0.00684	CbGeAlD
Nilotinib—LCK—heart—coronary artery disease	0.000316	0.00684	CbGeAlD
Nilotinib—Imatinib—KIT—coronary artery disease	0.000313	0.117	CrCbGaD
Nilotinib—PDGFRB—cardiac ventricle—coronary artery disease	0.000311	0.00671	CbGeAlD
Nilotinib—BRAF—blood—coronary artery disease	0.00031	0.00671	CbGeAlD
Nilotinib—CA14—heart—coronary artery disease	0.000309	0.00668	CbGeAlD
Nilotinib—EPHB4—heart—coronary artery disease	0.000301	0.00651	CbGeAlD
Nilotinib—MAPK14—cardiovascular system—coronary artery disease	0.0003	0.00648	CbGeAlD
Nilotinib—KIT—myocardium—coronary artery disease	0.000299	0.00646	CbGeAlD
Nilotinib—FGR—cardiovascular system—coronary artery disease	0.000299	0.00645	CbGeAlD
Nilotinib—EPHA2—heart—coronary artery disease	0.000295	0.00639	CbGeAlD
Nilotinib—EPHA4—cardiac atrium—coronary artery disease	0.000295	0.00637	CbGeAlD
Nilotinib—PDGFRB—myocardium—coronary artery disease	0.000292	0.00631	CbGeAlD
Nilotinib—CA3—cardiac atrium—coronary artery disease	0.000291	0.00629	CbGeAlD
Nilotinib—TEK—heart—coronary artery disease	0.000288	0.00623	CbGeAlD
Nilotinib—EPHB4—cardiovascular system—coronary artery disease	0.000284	0.00614	CbGeAlD
Nilotinib—HCK—blood—coronary artery disease	0.000283	0.00611	CbGeAlD
Nilotinib—ABL2—blood—coronary artery disease	0.000281	0.00608	CbGeAlD
Nilotinib—EPHA2—cardiovascular system—coronary artery disease	0.000279	0.00603	CbGeAlD
Nilotinib—ABL1—cardiac ventricle—coronary artery disease	0.000277	0.00598	CbGeAlD
Nilotinib—EPHB6—heart—coronary artery disease	0.000275	0.00595	CbGeAlD
Nilotinib—TEK—cardiovascular system—coronary artery disease	0.000272	0.00588	CbGeAlD
Nilotinib—CA14—cardiac atrium—coronary artery disease	0.000264	0.00571	CbGeAlD
Nilotinib—PDGFRA—heart—coronary artery disease	0.000261	0.00564	CbGeAlD
Nilotinib—ABL1—myocardium—coronary artery disease	0.00026	0.00563	CbGeAlD
Nilotinib—EPHB4—cardiac atrium—coronary artery disease	0.000258	0.00557	CbGeAlD
Nilotinib—EPHA4—blood—coronary artery disease	0.000257	0.00556	CbGeAlD
Nilotinib—EPHA2—cardiac atrium—coronary artery disease	0.000253	0.00546	CbGeAlD
Nilotinib—TEK—cardiac atrium—coronary artery disease	0.000246	0.00533	CbGeAlD
Nilotinib—PDGFRA—cardiovascular system—coronary artery disease	0.000246	0.00533	CbGeAlD
Nilotinib—MAPK14—blood—coronary artery disease	0.000237	0.00512	CbGeAlD
Nilotinib—FGR—blood—coronary artery disease	0.000236	0.0051	CbGeAlD
Nilotinib—LCK—blood—coronary artery disease	0.000236	0.0051	CbGeAlD
Nilotinib—EPHB6—cardiac atrium—coronary artery disease	0.000236	0.00509	CbGeAlD
Nilotinib—MAP2K5—heart—coronary artery disease	0.000236	0.00509	CbGeAlD
Nilotinib—CSF1R—heart—coronary artery disease	0.00023	0.00497	CbGeAlD
Nilotinib—CA4—cardiac ventricle—coronary artery disease	0.000227	0.00491	CbGeAlD
Nilotinib—EPHB4—blood—coronary artery disease	0.000225	0.00486	CbGeAlD
Nilotinib—MAP2K5—cardiovascular system—coronary artery disease	0.000222	0.0048	CbGeAlD
Nilotinib—EPHA2—blood—coronary artery disease	0.00022	0.00477	CbGeAlD
Nilotinib—CSF1R—cardiovascular system—coronary artery disease	0.000217	0.00469	CbGeAlD
Nilotinib—TEK—blood—coronary artery disease	0.000215	0.00465	CbGeAlD
Nilotinib—CA4—myocardium—coronary artery disease	0.000214	0.00462	CbGeAlD
Nilotinib—KIT—heart—coronary artery disease	0.000209	0.00451	CbGeAlD
Nilotinib—EPHB6—blood—coronary artery disease	0.000206	0.00444	CbGeAlD
Nilotinib—PDGFRB—heart—coronary artery disease	0.000204	0.00441	CbGeAlD
Nilotinib—MAP2K5—cardiac atrium—coronary artery disease	0.000201	0.00435	CbGeAlD
Nilotinib—KIT—cardiovascular system—coronary artery disease	0.000197	0.00426	CbGeAlD
Nilotinib—CSF1R—cardiac atrium—coronary artery disease	0.000197	0.00425	CbGeAlD
Nilotinib—PDGFRA—blood—coronary artery disease	0.000195	0.00421	CbGeAlD
Nilotinib—PDGFRB—cardiovascular system—coronary artery disease	0.000192	0.00416	CbGeAlD
Nilotinib—CA1—heart—coronary artery disease	0.000191	0.00413	CbGeAlD
Nilotinib—CA2—cardiac ventricle—coronary artery disease	0.000188	0.00407	CbGeAlD
Nilotinib—UGT1A1—blood—coronary artery disease	0.000186	0.00402	CbGeAlD
Nilotinib—ABL1—heart—coronary artery disease	0.000182	0.00393	CbGeAlD
Nilotinib—CA1—cardiovascular system—coronary artery disease	0.00018	0.00389	CbGeAlD
Nilotinib—CA2—myocardium—coronary artery disease	0.000177	0.00383	CbGeAlD
Nilotinib—MAP2K5—blood—coronary artery disease	0.000176	0.0038	CbGeAlD
Nilotinib—PDGFRB—cardiac atrium—coronary artery disease	0.000174	0.00377	CbGeAlD
Nilotinib—CSF1R—blood—coronary artery disease	0.000172	0.00371	CbGeAlD
Nilotinib—ABL1—cardiovascular system—coronary artery disease	0.000171	0.00371	CbGeAlD
Nilotinib—KIT—blood—coronary artery disease	0.000156	0.00337	CbGeAlD
Nilotinib—ABL1—cardiac atrium—coronary artery disease	0.000155	0.00336	CbGeAlD
Nilotinib—PDGFRB—blood—coronary artery disease	0.000152	0.00329	CbGeAlD
Nilotinib—CA4—heart—coronary artery disease	0.000149	0.00323	CbGeAlD
Nilotinib—CA1—blood—coronary artery disease	0.000142	0.00308	CbGeAlD
Nilotinib—CA4—cardiovascular system—coronary artery disease	0.000141	0.00304	CbGeAlD
Nilotinib—Imatinib—CYP2C19—coronary artery disease	0.000136	0.0509	CrCbGaD
Nilotinib—ABL1—blood—coronary artery disease	0.000136	0.00293	CbGeAlD
Nilotinib—CA4—cardiac atrium—coronary artery disease	0.000128	0.00276	CbGeAlD
Nilotinib—CA2—heart—coronary artery disease	0.000124	0.00267	CbGeAlD
Nilotinib—CA2—cardiovascular system—coronary artery disease	0.000117	0.00252	CbGeAlD
Nilotinib—ABCG2—heart—coronary artery disease	0.000115	0.00248	CbGeAlD
Nilotinib—CA4—blood—coronary artery disease	0.000111	0.00241	CbGeAlD
Nilotinib—CA2—cardiac atrium—coronary artery disease	0.000106	0.00229	CbGeAlD
Nilotinib—CYP2B6—heart—coronary artery disease	0.000106	0.00229	CbGeAlD
Nilotinib—CYP2C9—heart—coronary artery disease	0.000105	0.00226	CbGeAlD
Nilotinib—CYP2B6—cardiovascular system—coronary artery disease	9.97e-05	0.00216	CbGeAlD
Nilotinib—CYP2C9—cardiovascular system—coronary artery disease	9.88e-05	0.00214	CbGeAlD
Nilotinib—CA2—blood—coronary artery disease	9.23e-05	0.002	CbGeAlD
Nilotinib—CYP2C8—blood—coronary artery disease	8.79e-05	0.0019	CbGeAlD
Nilotinib—ABCG2—blood—coronary artery disease	8.55e-05	0.00185	CbGeAlD
Nilotinib—CYP2B6—blood—coronary artery disease	7.89e-05	0.00171	CbGeAlD
Nilotinib—CYP2C9—blood—coronary artery disease	7.81e-05	0.00169	CbGeAlD
Nilotinib—Imatinib—ALB—coronary artery disease	7.56e-05	0.0282	CrCbGaD
Nilotinib—CYP3A4—blood—coronary artery disease	5.96e-05	0.00129	CbGeAlD
Nilotinib—CYP2D6—blood—coronary artery disease	5.86e-05	0.00127	CbGeAlD
Nilotinib—ABCB1—heart—coronary artery disease	5.65e-05	0.00122	CbGeAlD
Nilotinib—ABCB1—cardiovascular system—coronary artery disease	5.33e-05	0.00115	CbGeAlD
Nilotinib—ABCB1—blood—coronary artery disease	4.22e-05	0.000911	CbGeAlD
Nilotinib—Dermatitis—Ezetimibe—coronary artery disease	2.3e-05	0.000174	CcSEcCtD
Nilotinib—Confusional state—Ramipril—coronary artery disease	2.3e-05	0.000174	CcSEcCtD
Nilotinib—Discomfort—Timolol—coronary artery disease	2.3e-05	0.000174	CcSEcCtD
Nilotinib—Asthenia—Niacin—coronary artery disease	2.3e-05	0.000173	CcSEcCtD
Nilotinib—Fatigue—Losartan—coronary artery disease	2.29e-05	0.000173	CcSEcCtD
Nilotinib—Headache—Ezetimibe—coronary artery disease	2.29e-05	0.000173	CcSEcCtD
Nilotinib—Malaise—Lisinopril—coronary artery disease	2.29e-05	0.000173	CcSEcCtD
Nilotinib—Oedema—Ramipril—coronary artery disease	2.28e-05	0.000172	CcSEcCtD
Nilotinib—Vertigo—Lisinopril—coronary artery disease	2.28e-05	0.000172	CcSEcCtD
Nilotinib—Dry mouth—Timolol—coronary artery disease	2.28e-05	0.000172	CcSEcCtD
Nilotinib—Constipation—Losartan—coronary artery disease	2.28e-05	0.000172	CcSEcCtD
Nilotinib—Pain—Losartan—coronary artery disease	2.28e-05	0.000172	CcSEcCtD
Nilotinib—Syncope—Lisinopril—coronary artery disease	2.27e-05	0.000172	CcSEcCtD
Nilotinib—Vomiting—Eplerenone—coronary artery disease	2.27e-05	0.000172	CcSEcCtD
Nilotinib—Feeling abnormal—Furosemide—coronary artery disease	2.27e-05	0.000172	CcSEcCtD
Nilotinib—Leukopenia—Lisinopril—coronary artery disease	2.27e-05	0.000171	CcSEcCtD
Nilotinib—Nausea—Fenofibrate—coronary artery disease	2.27e-05	0.000171	CcSEcCtD
Nilotinib—Pruritus—Niacin—coronary artery disease	2.26e-05	0.000171	CcSEcCtD
Nilotinib—Asthenia—Pravastatin—coronary artery disease	2.26e-05	0.000171	CcSEcCtD
Nilotinib—Gastrointestinal pain—Furosemide—coronary artery disease	2.26e-05	0.00017	CcSEcCtD
Nilotinib—Rash—Eplerenone—coronary artery disease	2.26e-05	0.00017	CcSEcCtD
Nilotinib—Urticaria—Perindopril—coronary artery disease	2.25e-05	0.00017	CcSEcCtD
Nilotinib—Hypersensitivity—Trandolapril—coronary artery disease	2.25e-05	0.00017	CcSEcCtD
Nilotinib—Dermatitis—Eplerenone—coronary artery disease	2.25e-05	0.00017	CcSEcCtD
Nilotinib—Diarrhoea—Valsartan—coronary artery disease	2.25e-05	0.00017	CcSEcCtD
Nilotinib—Confusional state—Timolol—coronary artery disease	2.25e-05	0.00017	CcSEcCtD
Nilotinib—Shock—Ramipril—coronary artery disease	2.25e-05	0.00017	CcSEcCtD
Nilotinib—Hypersensitivity—Enalapril—coronary artery disease	2.24e-05	0.00017	CcSEcCtD
Nilotinib—Body temperature increased—Perindopril—coronary artery disease	2.24e-05	0.000169	CcSEcCtD
Nilotinib—Abdominal pain—Perindopril—coronary artery disease	2.24e-05	0.000169	CcSEcCtD
Nilotinib—Palpitations—Lisinopril—coronary artery disease	2.24e-05	0.000169	CcSEcCtD
Nilotinib—Diarrhoea—Olmesartan—coronary artery disease	2.24e-05	0.000169	CcSEcCtD
Nilotinib—Headache—Eplerenone—coronary artery disease	2.24e-05	0.000169	CcSEcCtD
Nilotinib—Nervous system disorder—Ramipril—coronary artery disease	2.24e-05	0.000169	CcSEcCtD
Nilotinib—Thrombocytopenia—Ramipril—coronary artery disease	2.23e-05	0.000169	CcSEcCtD
Nilotinib—Oedema—Timolol—coronary artery disease	2.23e-05	0.000169	CcSEcCtD
Nilotinib—Pruritus—Pravastatin—coronary artery disease	2.23e-05	0.000168	CcSEcCtD
Nilotinib—Loss of consciousness—Lisinopril—coronary artery disease	2.23e-05	0.000168	CcSEcCtD
Nilotinib—Nausea—Clopidogrel—coronary artery disease	2.23e-05	0.000168	CcSEcCtD
Nilotinib—Tachycardia—Ramipril—coronary artery disease	2.23e-05	0.000168	CcSEcCtD
Nilotinib—Skin disorder—Ramipril—coronary artery disease	2.22e-05	0.000167	CcSEcCtD
Nilotinib—Infection—Timolol—coronary artery disease	2.22e-05	0.000167	CcSEcCtD
Nilotinib—Vomiting—Simvastatin—coronary artery disease	2.22e-05	0.000167	CcSEcCtD
Nilotinib—Hypersensitivity—Telmisartan—coronary artery disease	2.21e-05	0.000167	CcSEcCtD
Nilotinib—Cough—Lisinopril—coronary artery disease	2.21e-05	0.000167	CcSEcCtD
Nilotinib—Nausea—Lovastatin—coronary artery disease	2.21e-05	0.000167	CcSEcCtD
Nilotinib—Hyperhidrosis—Ramipril—coronary artery disease	2.21e-05	0.000167	CcSEcCtD
Nilotinib—Rash—Simvastatin—coronary artery disease	2.2e-05	0.000166	CcSEcCtD
Nilotinib—Dermatitis—Simvastatin—coronary artery disease	2.2e-05	0.000166	CcSEcCtD
Nilotinib—Asthenia—Trandolapril—coronary artery disease	2.2e-05	0.000166	CcSEcCtD
Nilotinib—Shock—Timolol—coronary artery disease	2.19e-05	0.000166	CcSEcCtD
Nilotinib—Feeling abnormal—Losartan—coronary artery disease	2.19e-05	0.000166	CcSEcCtD
Nilotinib—Urticaria—Furosemide—coronary artery disease	2.19e-05	0.000166	CcSEcCtD
Nilotinib—Diarrhoea—Niacin—coronary artery disease	2.19e-05	0.000165	CcSEcCtD
Nilotinib—Nervous system disorder—Timolol—coronary artery disease	2.19e-05	0.000165	CcSEcCtD
Nilotinib—Asthenia—Enalapril—coronary artery disease	2.19e-05	0.000165	CcSEcCtD
Nilotinib—Headache—Simvastatin—coronary artery disease	2.18e-05	0.000165	CcSEcCtD
Nilotinib—Abdominal pain—Furosemide—coronary artery disease	2.18e-05	0.000165	CcSEcCtD
Nilotinib—Body temperature increased—Furosemide—coronary artery disease	2.18e-05	0.000165	CcSEcCtD
Nilotinib—Gastrointestinal pain—Losartan—coronary artery disease	2.18e-05	0.000164	CcSEcCtD
Nilotinib—Dizziness—Valsartan—coronary artery disease	2.18e-05	0.000164	CcSEcCtD
Nilotinib—Anorexia—Ramipril—coronary artery disease	2.18e-05	0.000164	CcSEcCtD
Nilotinib—Nausea—Ezetimibe—coronary artery disease	2.17e-05	0.000164	CcSEcCtD
Nilotinib—Skin disorder—Timolol—coronary artery disease	2.17e-05	0.000164	CcSEcCtD
Nilotinib—Dizziness—Olmesartan—coronary artery disease	2.17e-05	0.000164	CcSEcCtD
Nilotinib—Pruritus—Trandolapril—coronary artery disease	2.16e-05	0.000164	CcSEcCtD
Nilotinib—Myalgia—Lisinopril—coronary artery disease	2.16e-05	0.000163	CcSEcCtD
Nilotinib—Chest pain—Lisinopril—coronary artery disease	2.16e-05	0.000163	CcSEcCtD
Nilotinib—Arthralgia—Lisinopril—coronary artery disease	2.16e-05	0.000163	CcSEcCtD
Nilotinib—Hyperhidrosis—Timolol—coronary artery disease	2.16e-05	0.000163	CcSEcCtD
Nilotinib—Asthenia—Telmisartan—coronary artery disease	2.16e-05	0.000163	CcSEcCtD
Nilotinib—Pruritus—Enalapril—coronary artery disease	2.16e-05	0.000163	CcSEcCtD
Nilotinib—Diarrhoea—Pravastatin—coronary artery disease	2.16e-05	0.000163	CcSEcCtD
Nilotinib—Anxiety—Lisinopril—coronary artery disease	2.15e-05	0.000163	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	2.14e-05	0.000162	CcSEcCtD
Nilotinib—Discomfort—Lisinopril—coronary artery disease	2.13e-05	0.000161	CcSEcCtD
Nilotinib—Hypotension—Ramipril—coronary artery disease	2.13e-05	0.000161	CcSEcCtD
Nilotinib—Anorexia—Timolol—coronary artery disease	2.13e-05	0.000161	CcSEcCtD
Nilotinib—Pruritus—Telmisartan—coronary artery disease	2.13e-05	0.000161	CcSEcCtD
Nilotinib—Nausea—Eplerenone—coronary artery disease	2.12e-05	0.00016	CcSEcCtD
Nilotinib—Dizziness—Niacin—coronary artery disease	2.12e-05	0.00016	CcSEcCtD
Nilotinib—Urticaria—Losartan—coronary artery disease	2.11e-05	0.00016	CcSEcCtD
Nilotinib—Dry mouth—Lisinopril—coronary artery disease	2.11e-05	0.00016	CcSEcCtD
Nilotinib—Abdominal pain—Losartan—coronary artery disease	2.1e-05	0.000159	CcSEcCtD
Nilotinib—Body temperature increased—Losartan—coronary artery disease	2.1e-05	0.000159	CcSEcCtD
Nilotinib—Asthenia—Captopril—coronary artery disease	2.1e-05	0.000158	CcSEcCtD
Nilotinib—Diarrhoea—Trandolapril—coronary artery disease	2.09e-05	0.000158	CcSEcCtD
Nilotinib—Vomiting—Valsartan—coronary artery disease	2.09e-05	0.000158	CcSEcCtD
Nilotinib—Confusional state—Lisinopril—coronary artery disease	2.09e-05	0.000158	CcSEcCtD
Nilotinib—Diarrhoea—Enalapril—coronary artery disease	2.08e-05	0.000158	CcSEcCtD
Nilotinib—Hypotension—Timolol—coronary artery disease	2.08e-05	0.000157	CcSEcCtD
Nilotinib—Dizziness—Pravastatin—coronary artery disease	2.08e-05	0.000157	CcSEcCtD
Nilotinib—Vomiting—Olmesartan—coronary artery disease	2.08e-05	0.000157	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Ramipril—coronary artery disease	2.08e-05	0.000157	CcSEcCtD
Nilotinib—Rash—Valsartan—coronary artery disease	2.07e-05	0.000157	CcSEcCtD
Nilotinib—Dermatitis—Valsartan—coronary artery disease	2.07e-05	0.000157	CcSEcCtD
Nilotinib—Nausea—Simvastatin—coronary artery disease	2.07e-05	0.000156	CcSEcCtD
Nilotinib—Oedema—Lisinopril—coronary artery disease	2.07e-05	0.000156	CcSEcCtD
Nilotinib—Pruritus—Captopril—coronary artery disease	2.07e-05	0.000156	CcSEcCtD
Nilotinib—Rash—Olmesartan—coronary artery disease	2.06e-05	0.000156	CcSEcCtD
Nilotinib—Insomnia—Ramipril—coronary artery disease	2.06e-05	0.000156	CcSEcCtD
Nilotinib—Dermatitis—Olmesartan—coronary artery disease	2.06e-05	0.000156	CcSEcCtD
Nilotinib—Headache—Valsartan—coronary artery disease	2.06e-05	0.000156	CcSEcCtD
Nilotinib—Diarrhoea—Telmisartan—coronary artery disease	2.06e-05	0.000155	CcSEcCtD
Nilotinib—Infection—Lisinopril—coronary artery disease	2.06e-05	0.000155	CcSEcCtD
Nilotinib—Headache—Olmesartan—coronary artery disease	2.05e-05	0.000155	CcSEcCtD
Nilotinib—Paraesthesia—Ramipril—coronary artery disease	2.05e-05	0.000155	CcSEcCtD
Nilotinib—Shock—Lisinopril—coronary artery disease	2.04e-05	0.000154	CcSEcCtD
Nilotinib—Asthenia—Perindopril—coronary artery disease	2.04e-05	0.000154	CcSEcCtD
Nilotinib—Dyspnoea—Ramipril—coronary artery disease	2.03e-05	0.000154	CcSEcCtD
Nilotinib—Vomiting—Niacin—coronary artery disease	2.03e-05	0.000154	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Timolol—coronary artery disease	2.03e-05	0.000154	CcSEcCtD
Nilotinib—Hypersensitivity—Furosemide—coronary artery disease	2.03e-05	0.000154	CcSEcCtD
Nilotinib—Thrombocytopenia—Lisinopril—coronary artery disease	2.03e-05	0.000153	CcSEcCtD
Nilotinib—Dizziness—Trandolapril—coronary artery disease	2.02e-05	0.000153	CcSEcCtD
Nilotinib—Tachycardia—Lisinopril—coronary artery disease	2.02e-05	0.000153	CcSEcCtD
Nilotinib—Insomnia—Timolol—coronary artery disease	2.02e-05	0.000152	CcSEcCtD
Nilotinib—Rash—Niacin—coronary artery disease	2.02e-05	0.000152	CcSEcCtD
Nilotinib—Dermatitis—Niacin—coronary artery disease	2.02e-05	0.000152	CcSEcCtD
Nilotinib—Dizziness—Enalapril—coronary artery disease	2.01e-05	0.000152	CcSEcCtD
Nilotinib—Skin disorder—Lisinopril—coronary artery disease	2.01e-05	0.000152	CcSEcCtD
Nilotinib—Dyspepsia—Ramipril—coronary artery disease	2.01e-05	0.000152	CcSEcCtD
Nilotinib—Pruritus—Perindopril—coronary artery disease	2.01e-05	0.000152	CcSEcCtD
Nilotinib—Headache—Niacin—coronary artery disease	2e-05	0.000151	CcSEcCtD
Nilotinib—Paraesthesia—Timolol—coronary artery disease	2e-05	0.000151	CcSEcCtD
Nilotinib—Vomiting—Pravastatin—coronary artery disease	2e-05	0.000151	CcSEcCtD
Nilotinib—Hyperhidrosis—Lisinopril—coronary artery disease	2e-05	0.000151	CcSEcCtD
Nilotinib—Diarrhoea—Captopril—coronary artery disease	2e-05	0.000151	CcSEcCtD
Nilotinib—Dyspnoea—Timolol—coronary artery disease	1.99e-05	0.00015	CcSEcCtD
Nilotinib—Dizziness—Telmisartan—coronary artery disease	1.99e-05	0.00015	CcSEcCtD
Nilotinib—Rash—Pravastatin—coronary artery disease	1.99e-05	0.00015	CcSEcCtD
Nilotinib—Dermatitis—Pravastatin—coronary artery disease	1.98e-05	0.00015	CcSEcCtD
Nilotinib—Decreased appetite—Ramipril—coronary artery disease	1.98e-05	0.00015	CcSEcCtD
Nilotinib—Asthenia—Furosemide—coronary artery disease	1.98e-05	0.00015	CcSEcCtD
Nilotinib—Headache—Pravastatin—coronary artery disease	1.97e-05	0.000149	CcSEcCtD
Nilotinib—Anorexia—Lisinopril—coronary artery disease	1.97e-05	0.000149	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Ramipril—coronary artery disease	1.97e-05	0.000149	CcSEcCtD
Nilotinib—Fatigue—Ramipril—coronary artery disease	1.97e-05	0.000149	CcSEcCtD
Nilotinib—Dyspepsia—Timolol—coronary artery disease	1.96e-05	0.000148	CcSEcCtD
Nilotinib—Hypersensitivity—Losartan—coronary artery disease	1.96e-05	0.000148	CcSEcCtD
Nilotinib—Nausea—Valsartan—coronary artery disease	1.95e-05	0.000148	CcSEcCtD
Nilotinib—Pruritus—Furosemide—coronary artery disease	1.95e-05	0.000147	CcSEcCtD
Nilotinib—Constipation—Ramipril—coronary artery disease	1.95e-05	0.000147	CcSEcCtD
Nilotinib—Nausea—Olmesartan—coronary artery disease	1.95e-05	0.000147	CcSEcCtD
Nilotinib—Vomiting—Trandolapril—coronary artery disease	1.95e-05	0.000147	CcSEcCtD
Nilotinib—Diarrhoea—Perindopril—coronary artery disease	1.94e-05	0.000147	CcSEcCtD
Nilotinib—Decreased appetite—Timolol—coronary artery disease	1.94e-05	0.000147	CcSEcCtD
Nilotinib—Vomiting—Enalapril—coronary artery disease	1.94e-05	0.000146	CcSEcCtD
Nilotinib—Hypotension—Lisinopril—coronary artery disease	1.93e-05	0.000146	CcSEcCtD
Nilotinib—Dizziness—Captopril—coronary artery disease	1.93e-05	0.000146	CcSEcCtD
Nilotinib—Rash—Trandolapril—coronary artery disease	1.93e-05	0.000146	CcSEcCtD
Nilotinib—Dermatitis—Trandolapril—coronary artery disease	1.93e-05	0.000146	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Timolol—coronary artery disease	1.93e-05	0.000146	CcSEcCtD
Nilotinib—Fatigue—Timolol—coronary artery disease	1.92e-05	0.000145	CcSEcCtD
Nilotinib—Rash—Enalapril—coronary artery disease	1.92e-05	0.000145	CcSEcCtD
Nilotinib—Dermatitis—Enalapril—coronary artery disease	1.92e-05	0.000145	CcSEcCtD
Nilotinib—Headache—Trandolapril—coronary artery disease	1.92e-05	0.000145	CcSEcCtD
Nilotinib—Vomiting—Telmisartan—coronary artery disease	1.91e-05	0.000144	CcSEcCtD
Nilotinib—Asthenia—Losartan—coronary artery disease	1.91e-05	0.000144	CcSEcCtD
Nilotinib—Headache—Enalapril—coronary artery disease	1.91e-05	0.000144	CcSEcCtD
Nilotinib—Pain—Timolol—coronary artery disease	1.91e-05	0.000144	CcSEcCtD
Nilotinib—Nausea—Niacin—coronary artery disease	1.9e-05	0.000144	CcSEcCtD
Nilotinib—Rash—Telmisartan—coronary artery disease	1.89e-05	0.000143	CcSEcCtD
Nilotinib—Dermatitis—Telmisartan—coronary artery disease	1.89e-05	0.000143	CcSEcCtD
Nilotinib—Diarrhoea—Furosemide—coronary artery disease	1.89e-05	0.000143	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Lisinopril—coronary artery disease	1.89e-05	0.000142	CcSEcCtD
Nilotinib—Pruritus—Losartan—coronary artery disease	1.88e-05	0.000142	CcSEcCtD
Nilotinib—Headache—Telmisartan—coronary artery disease	1.88e-05	0.000142	CcSEcCtD
Nilotinib—Feeling abnormal—Ramipril—coronary artery disease	1.88e-05	0.000142	CcSEcCtD
Nilotinib—Dizziness—Perindopril—coronary artery disease	1.88e-05	0.000142	CcSEcCtD
Nilotinib—Insomnia—Lisinopril—coronary artery disease	1.87e-05	0.000141	CcSEcCtD
Nilotinib—Nausea—Pravastatin—coronary artery disease	1.87e-05	0.000141	CcSEcCtD
Nilotinib—Gastrointestinal pain—Ramipril—coronary artery disease	1.87e-05	0.000141	CcSEcCtD
Nilotinib—Paraesthesia—Lisinopril—coronary artery disease	1.86e-05	0.00014	CcSEcCtD
Nilotinib—Vomiting—Captopril—coronary artery disease	1.86e-05	0.00014	CcSEcCtD
Nilotinib—Dyspnoea—Lisinopril—coronary artery disease	1.85e-05	0.000139	CcSEcCtD
Nilotinib—Rash—Captopril—coronary artery disease	1.84e-05	0.000139	CcSEcCtD
Nilotinib—Dermatitis—Captopril—coronary artery disease	1.84e-05	0.000139	CcSEcCtD
Nilotinib—Feeling abnormal—Timolol—coronary artery disease	1.84e-05	0.000139	CcSEcCtD
Nilotinib—Headache—Captopril—coronary artery disease	1.83e-05	0.000138	CcSEcCtD
Nilotinib—Gastrointestinal pain—Timolol—coronary artery disease	1.82e-05	0.000138	CcSEcCtD
Nilotinib—Dizziness—Furosemide—coronary artery disease	1.82e-05	0.000138	CcSEcCtD
Nilotinib—Dyspepsia—Lisinopril—coronary artery disease	1.82e-05	0.000138	CcSEcCtD
Nilotinib—Diarrhoea—Losartan—coronary artery disease	1.82e-05	0.000138	CcSEcCtD
Nilotinib—Nausea—Trandolapril—coronary artery disease	1.82e-05	0.000137	CcSEcCtD
Nilotinib—Urticaria—Ramipril—coronary artery disease	1.81e-05	0.000137	CcSEcCtD
Nilotinib—Nausea—Enalapril—coronary artery disease	1.81e-05	0.000137	CcSEcCtD
Nilotinib—Vomiting—Perindopril—coronary artery disease	1.8e-05	0.000136	CcSEcCtD
Nilotinib—Body temperature increased—Ramipril—coronary artery disease	1.8e-05	0.000136	CcSEcCtD
Nilotinib—Abdominal pain—Ramipril—coronary artery disease	1.8e-05	0.000136	CcSEcCtD
Nilotinib—Decreased appetite—Lisinopril—coronary artery disease	1.8e-05	0.000136	CcSEcCtD
Nilotinib—Rash—Perindopril—coronary artery disease	1.79e-05	0.000135	CcSEcCtD
Nilotinib—Dermatitis—Perindopril—coronary artery disease	1.79e-05	0.000135	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Lisinopril—coronary artery disease	1.79e-05	0.000135	CcSEcCtD
Nilotinib—Nausea—Telmisartan—coronary artery disease	1.79e-05	0.000135	CcSEcCtD
Nilotinib—Fatigue—Lisinopril—coronary artery disease	1.78e-05	0.000135	CcSEcCtD
Nilotinib—Headache—Perindopril—coronary artery disease	1.78e-05	0.000134	CcSEcCtD
Nilotinib—Urticaria—Timolol—coronary artery disease	1.77e-05	0.000134	CcSEcCtD
Nilotinib—Pain—Lisinopril—coronary artery disease	1.77e-05	0.000134	CcSEcCtD
Nilotinib—Constipation—Lisinopril—coronary artery disease	1.77e-05	0.000134	CcSEcCtD
Nilotinib—Abdominal pain—Timolol—coronary artery disease	1.76e-05	0.000133	CcSEcCtD
Nilotinib—Body temperature increased—Timolol—coronary artery disease	1.76e-05	0.000133	CcSEcCtD
Nilotinib—Dizziness—Losartan—coronary artery disease	1.76e-05	0.000133	CcSEcCtD
Nilotinib—Vomiting—Furosemide—coronary artery disease	1.75e-05	0.000133	CcSEcCtD
Nilotinib—Rash—Furosemide—coronary artery disease	1.74e-05	0.000131	CcSEcCtD
Nilotinib—Dermatitis—Furosemide—coronary artery disease	1.74e-05	0.000131	CcSEcCtD
Nilotinib—Nausea—Captopril—coronary artery disease	1.74e-05	0.000131	CcSEcCtD
Nilotinib—Headache—Furosemide—coronary artery disease	1.73e-05	0.000131	CcSEcCtD
Nilotinib—Feeling abnormal—Lisinopril—coronary artery disease	1.71e-05	0.000129	CcSEcCtD
Nilotinib—Gastrointestinal pain—Lisinopril—coronary artery disease	1.69e-05	0.000128	CcSEcCtD
Nilotinib—Vomiting—Losartan—coronary artery disease	1.69e-05	0.000128	CcSEcCtD
Nilotinib—Nausea—Perindopril—coronary artery disease	1.69e-05	0.000127	CcSEcCtD
Nilotinib—Hypersensitivity—Ramipril—coronary artery disease	1.68e-05	0.000127	CcSEcCtD
Nilotinib—Rash—Losartan—coronary artery disease	1.68e-05	0.000127	CcSEcCtD
Nilotinib—Dermatitis—Losartan—coronary artery disease	1.68e-05	0.000127	CcSEcCtD
Nilotinib—Headache—Losartan—coronary artery disease	1.67e-05	0.000126	CcSEcCtD
Nilotinib—Urticaria—Lisinopril—coronary artery disease	1.64e-05	0.000124	CcSEcCtD
Nilotinib—Hypersensitivity—Timolol—coronary artery disease	1.64e-05	0.000124	CcSEcCtD
Nilotinib—Nausea—Furosemide—coronary artery disease	1.64e-05	0.000124	CcSEcCtD
Nilotinib—Asthenia—Ramipril—coronary artery disease	1.64e-05	0.000124	CcSEcCtD
Nilotinib—Abdominal pain—Lisinopril—coronary artery disease	1.64e-05	0.000124	CcSEcCtD
Nilotinib—Body temperature increased—Lisinopril—coronary artery disease	1.64e-05	0.000124	CcSEcCtD
Nilotinib—Pruritus—Ramipril—coronary artery disease	1.61e-05	0.000122	CcSEcCtD
Nilotinib—Asthenia—Timolol—coronary artery disease	1.6e-05	0.000121	CcSEcCtD
Nilotinib—Nausea—Losartan—coronary artery disease	1.58e-05	0.000119	CcSEcCtD
Nilotinib—Pruritus—Timolol—coronary artery disease	1.58e-05	0.000119	CcSEcCtD
Nilotinib—Diarrhoea—Ramipril—coronary artery disease	1.56e-05	0.000118	CcSEcCtD
Nilotinib—Diarrhoea—Timolol—coronary artery disease	1.53e-05	0.000115	CcSEcCtD
Nilotinib—Hypersensitivity—Lisinopril—coronary artery disease	1.52e-05	0.000115	CcSEcCtD
Nilotinib—Dizziness—Ramipril—coronary artery disease	1.51e-05	0.000114	CcSEcCtD
Nilotinib—Asthenia—Lisinopril—coronary artery disease	1.48e-05	0.000112	CcSEcCtD
Nilotinib—Dizziness—Timolol—coronary artery disease	1.48e-05	0.000111	CcSEcCtD
Nilotinib—Pruritus—Lisinopril—coronary artery disease	1.46e-05	0.000111	CcSEcCtD
Nilotinib—Vomiting—Ramipril—coronary artery disease	1.45e-05	0.00011	CcSEcCtD
Nilotinib—Rash—Ramipril—coronary artery disease	1.44e-05	0.000109	CcSEcCtD
Nilotinib—Dermatitis—Ramipril—coronary artery disease	1.44e-05	0.000109	CcSEcCtD
Nilotinib—Headache—Ramipril—coronary artery disease	1.43e-05	0.000108	CcSEcCtD
Nilotinib—Vomiting—Timolol—coronary artery disease	1.42e-05	0.000107	CcSEcCtD
Nilotinib—Diarrhoea—Lisinopril—coronary artery disease	1.42e-05	0.000107	CcSEcCtD
Nilotinib—Rash—Timolol—coronary artery disease	1.41e-05	0.000106	CcSEcCtD
Nilotinib—Dermatitis—Timolol—coronary artery disease	1.41e-05	0.000106	CcSEcCtD
Nilotinib—Headache—Timolol—coronary artery disease	1.4e-05	0.000106	CcSEcCtD
Nilotinib—Dizziness—Lisinopril—coronary artery disease	1.37e-05	0.000103	CcSEcCtD
Nilotinib—Nausea—Ramipril—coronary artery disease	1.36e-05	0.000102	CcSEcCtD
Nilotinib—Nausea—Timolol—coronary artery disease	1.33e-05	0.0001	CcSEcCtD
Nilotinib—Vomiting—Lisinopril—coronary artery disease	1.32e-05	9.94e-05	CcSEcCtD
Nilotinib—Rash—Lisinopril—coronary artery disease	1.3e-05	9.86e-05	CcSEcCtD
Nilotinib—Dermatitis—Lisinopril—coronary artery disease	1.3e-05	9.85e-05	CcSEcCtD
Nilotinib—Headache—Lisinopril—coronary artery disease	1.3e-05	9.8e-05	CcSEcCtD
Nilotinib—Nausea—Lisinopril—coronary artery disease	1.23e-05	9.29e-05	CcSEcCtD
Nilotinib—CYP2B6—Metabolism—APOE—coronary artery disease	3.89e-07	3.06e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—coronary artery disease	3.86e-07	3.04e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JAK2—coronary artery disease	3.86e-07	3.04e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—coronary artery disease	3.85e-07	3.03e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOA1—coronary artery disease	3.84e-07	3.03e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6R—coronary artery disease	3.84e-07	3.02e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GPX1—coronary artery disease	3.83e-07	3.02e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PIK3CA—coronary artery disease	3.81e-07	3e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—coronary artery disease	3.81e-07	3e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTP1—coronary artery disease	3.79e-07	2.99e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—coronary artery disease	3.79e-07	2.99e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1—coronary artery disease	3.78e-07	2.98e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—VCAN—coronary artery disease	3.78e-07	2.98e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARGC1A—coronary artery disease	3.76e-07	2.96e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALDOA—coronary artery disease	3.75e-07	2.96e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HMOX1—coronary artery disease	3.74e-07	2.95e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PIK3CA—coronary artery disease	3.73e-07	2.94e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CD36—coronary artery disease	3.73e-07	2.94e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PIK3CA—coronary artery disease	3.72e-07	2.93e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—coronary artery disease	3.71e-07	2.92e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAT—coronary artery disease	3.69e-07	2.91e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPP2CA—coronary artery disease	3.68e-07	2.9e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—coronary artery disease	3.68e-07	2.9e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—coronary artery disease	3.66e-07	2.88e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DCN—coronary artery disease	3.64e-07	2.87e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—coronary artery disease	3.64e-07	2.87e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—coronary artery disease	3.64e-07	2.87e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—coronary artery disease	3.63e-07	2.86e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—coronary artery disease	3.63e-07	2.86e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—coronary artery disease	3.62e-07	2.86e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—coronary artery disease	3.61e-07	2.85e-06	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—coronary artery disease	3.61e-07	2.85e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—coronary artery disease	3.61e-07	2.85e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK1—coronary artery disease	3.6e-07	2.84e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SERPINE1—coronary artery disease	3.59e-07	2.83e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOB—coronary artery disease	3.58e-07	2.82e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTP1—coronary artery disease	3.57e-07	2.82e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK1—coronary artery disease	3.57e-07	2.81e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—coronary artery disease	3.57e-07	2.81e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—coronary artery disease	3.56e-07	2.81e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—coronary artery disease	3.55e-07	2.8e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALDH2—coronary artery disease	3.54e-07	2.79e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTP1—coronary artery disease	3.54e-07	2.79e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARGC1A—coronary artery disease	3.54e-07	2.79e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—coronary artery disease	3.54e-07	2.79e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—coronary artery disease	3.53e-07	2.78e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HMOX1—coronary artery disease	3.52e-07	2.78e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—coronary artery disease	3.52e-07	2.77e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARGC1A—coronary artery disease	3.51e-07	2.77e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HMOX1—coronary artery disease	3.49e-07	2.75e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTM1—coronary artery disease	3.49e-07	2.75e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAT—coronary artery disease	3.48e-07	2.74e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF2—coronary artery disease	3.48e-07	2.74e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—coronary artery disease	3.48e-07	2.74e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—coronary artery disease	3.46e-07	2.72e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LIPC—coronary artery disease	3.45e-07	2.72e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HBA1—coronary artery disease	3.45e-07	2.72e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2C19—coronary artery disease	3.45e-07	2.72e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	3.45e-07	2.72e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—coronary artery disease	3.45e-07	2.72e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAT—coronary artery disease	3.45e-07	2.72e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK1—coronary artery disease	3.44e-07	2.71e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—coronary artery disease	3.43e-07	2.71e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOC3—coronary artery disease	3.43e-07	2.7e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—coronary artery disease	3.43e-07	2.7e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—coronary artery disease	3.43e-07	2.7e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—LPL—coronary artery disease	3.42e-07	2.7e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—coronary artery disease	3.42e-07	2.69e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LDLR—coronary artery disease	3.41e-07	2.69e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—coronary artery disease	3.39e-07	2.67e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOB—coronary artery disease	3.38e-07	2.66e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—coronary artery disease	3.38e-07	2.66e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—coronary artery disease	3.37e-07	2.66e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—coronary artery disease	3.37e-07	2.66e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	3.37e-07	2.66e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—coronary artery disease	3.37e-07	2.65e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AGT—coronary artery disease	3.36e-07	2.65e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—coronary artery disease	3.36e-07	2.65e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOB—coronary artery disease	3.35e-07	2.64e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—coronary artery disease	3.34e-07	2.63e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GPX1—coronary artery disease	3.34e-07	2.63e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JAK2—coronary artery disease	3.33e-07	2.63e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CETP—coronary artery disease	3.33e-07	2.63e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCLC—coronary artery disease	3.33e-07	2.63e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—coronary artery disease	3.31e-07	2.61e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—coronary artery disease	3.3e-07	2.6e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SDC1—coronary artery disease	3.29e-07	2.6e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—coronary artery disease	3.29e-07	2.6e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—coronary artery disease	3.29e-07	2.59e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—coronary artery disease	3.29e-07	2.59e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—coronary artery disease	3.28e-07	2.59e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—coronary artery disease	3.28e-07	2.58e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—coronary artery disease	3.26e-07	2.57e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOA1—coronary artery disease	3.25e-07	2.56e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CD36—coronary artery disease	3.25e-07	2.56e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK1—coronary artery disease	3.25e-07	2.56e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—coronary artery disease	3.24e-07	2.55e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—coronary artery disease	3.22e-07	2.54e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—LPL—coronary artery disease	3.22e-07	2.54e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPP2CA—coronary artery disease	3.21e-07	2.53e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—coronary artery disease	3.21e-07	2.53e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—coronary artery disease	3.21e-07	2.53e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—LPL—coronary artery disease	3.2e-07	2.52e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—coronary artery disease	3.18e-07	2.51e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK1—coronary artery disease	3.18e-07	2.5e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX1—coronary artery disease	3.15e-07	2.48e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—coronary artery disease	3.14e-07	2.47e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—coronary artery disease	3.13e-07	2.46e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX1—coronary artery disease	3.12e-07	2.46e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	3.12e-07	2.46e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—coronary artery disease	3.11e-07	2.45e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PSMA6—coronary artery disease	3.11e-07	2.45e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PSMB5—coronary artery disease	3.11e-07	2.45e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—coronary artery disease	3.1e-07	2.44e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—coronary artery disease	3.08e-07	2.43e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—coronary artery disease	3.08e-07	2.43e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK1—coronary artery disease	3.08e-07	2.42e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CD36—coronary artery disease	3.06e-07	2.41e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—coronary artery disease	3.06e-07	2.41e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—coronary artery disease	3.05e-07	2.4e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—coronary artery disease	3.05e-07	2.4e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—coronary artery disease	3.04e-07	2.4e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—coronary artery disease	3.04e-07	2.4e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CTGF—coronary artery disease	3.04e-07	2.4e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—coronary artery disease	3.04e-07	2.39e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CD36—coronary artery disease	3.04e-07	2.39e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPP2CA—coronary artery disease	3.02e-07	2.38e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—coronary artery disease	3.01e-07	2.38e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GOT2—coronary artery disease	3.01e-07	2.37e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMGCR—coronary artery disease	3.01e-07	2.37e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPP2CA—coronary artery disease	3e-07	2.36e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—coronary artery disease	2.99e-07	2.35e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—coronary artery disease	2.98e-07	2.34e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—coronary artery disease	2.96e-07	2.33e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGT—coronary artery disease	2.93e-07	2.31e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—coronary artery disease	2.91e-07	2.3e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—coronary artery disease	2.91e-07	2.29e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—coronary artery disease	2.9e-07	2.29e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—coronary artery disease	2.88e-07	2.27e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—coronary artery disease	2.87e-07	2.26e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—coronary artery disease	2.87e-07	2.26e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—coronary artery disease	2.86e-07	2.25e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOA1—coronary artery disease	2.83e-07	2.23e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—coronary artery disease	2.83e-07	2.23e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—coronary artery disease	2.83e-07	2.23e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—coronary artery disease	2.83e-07	2.23e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—coronary artery disease	2.82e-07	2.22e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—coronary artery disease	2.82e-07	2.22e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—coronary artery disease	2.81e-07	2.21e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—coronary artery disease	2.8e-07	2.21e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK1—coronary artery disease	2.77e-07	2.18e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLCB1—coronary artery disease	2.77e-07	2.18e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—coronary artery disease	2.77e-07	2.18e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—coronary artery disease	2.77e-07	2.18e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGT—coronary artery disease	2.76e-07	2.17e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—coronary artery disease	2.76e-07	2.17e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—coronary artery disease	2.75e-07	2.17e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—coronary artery disease	2.74e-07	2.16e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGT—coronary artery disease	2.73e-07	2.15e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK1—coronary artery disease	2.71e-07	2.14e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—coronary artery disease	2.7e-07	2.13e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCA1—coronary artery disease	2.69e-07	2.12e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—coronary artery disease	2.68e-07	2.11e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOA1—coronary artery disease	2.67e-07	2.11e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—coronary artery disease	2.67e-07	2.1e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—coronary artery disease	2.66e-07	2.1e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOA1—coronary artery disease	2.65e-07	2.09e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—coronary artery disease	2.64e-07	2.08e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—coronary artery disease	2.64e-07	2.08e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—coronary artery disease	2.62e-07	2.07e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GGT1—coronary artery disease	2.6e-07	2.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GOT1—coronary artery disease	2.6e-07	2.05e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—coronary artery disease	2.58e-07	2.03e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK1—coronary artery disease	2.57e-07	2.03e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—coronary artery disease	2.55e-07	2.01e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	2.54e-07	2e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—coronary artery disease	2.53e-07	1.99e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—coronary artery disease	2.5e-07	1.97e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—coronary artery disease	2.5e-07	1.97e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—coronary artery disease	2.47e-07	1.95e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—coronary artery disease	2.47e-07	1.94e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—coronary artery disease	2.46e-07	1.94e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—coronary artery disease	2.44e-07	1.92e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—coronary artery disease	2.44e-07	1.92e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—coronary artery disease	2.4e-07	1.9e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—coronary artery disease	2.36e-07	1.86e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—coronary artery disease	2.35e-07	1.86e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—coronary artery disease	2.35e-07	1.85e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—coronary artery disease	2.34e-07	1.84e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—coronary artery disease	2.33e-07	1.84e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—coronary artery disease	2.32e-07	1.83e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	2.32e-07	1.82e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMOX1—coronary artery disease	2.3e-07	1.82e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—coronary artery disease	2.3e-07	1.82e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—coronary artery disease	2.3e-07	1.81e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAT—coronary artery disease	2.27e-07	1.79e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—coronary artery disease	2.27e-07	1.79e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—coronary artery disease	2.26e-07	1.78e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—coronary artery disease	2.25e-07	1.77e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—coronary artery disease	2.25e-07	1.77e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—coronary artery disease	2.24e-07	1.76e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—coronary artery disease	2.23e-07	1.76e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK1—coronary artery disease	2.22e-07	1.75e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOB—coronary artery disease	2.21e-07	1.74e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—coronary artery disease	2.18e-07	1.72e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—coronary artery disease	2.15e-07	1.7e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—coronary artery disease	2.15e-07	1.69e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—coronary artery disease	2.15e-07	1.69e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—coronary artery disease	2.13e-07	1.68e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—coronary artery disease	2.12e-07	1.67e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LPL—coronary artery disease	2.11e-07	1.66e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—coronary artery disease	2.1e-07	1.65e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—coronary artery disease	2.08e-07	1.64e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX1—coronary artery disease	2.06e-07	1.62e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—coronary artery disease	2.02e-07	1.6e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—coronary artery disease	2.01e-07	1.58e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CD36—coronary artery disease	2e-07	1.58e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	1.98e-07	1.56e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—coronary artery disease	1.98e-07	1.56e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—coronary artery disease	1.96e-07	1.55e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—coronary artery disease	1.96e-07	1.55e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—coronary artery disease	1.93e-07	1.52e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—coronary artery disease	1.92e-07	1.52e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—coronary artery disease	1.9e-07	1.5e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—coronary artery disease	1.85e-07	1.46e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—coronary artery disease	1.84e-07	1.45e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—coronary artery disease	1.83e-07	1.44e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—coronary artery disease	1.82e-07	1.44e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGT—coronary artery disease	1.8e-07	1.42e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—coronary artery disease	1.77e-07	1.39e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOA1—coronary artery disease	1.75e-07	1.38e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—coronary artery disease	1.71e-07	1.35e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—coronary artery disease	1.64e-07	1.29e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—coronary artery disease	1.58e-07	1.24e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—coronary artery disease	1.54e-07	1.21e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—coronary artery disease	1.52e-07	1.2e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—coronary artery disease	1.39e-07	1.09e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—coronary artery disease	1.38e-07	1.09e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—coronary artery disease	1.34e-07	1.06e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—coronary artery disease	1.32e-07	1.04e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—coronary artery disease	1.21e-07	9.54e-07	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—coronary artery disease	1.21e-07	9.53e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—coronary artery disease	1.14e-07	8.98e-07	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—coronary artery disease	1.13e-07	8.93e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—coronary artery disease	1.13e-07	8.9e-07	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—coronary artery disease	9.88e-08	7.78e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—coronary artery disease	9.31e-08	7.33e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—coronary artery disease	9.23e-08	7.27e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	7.45e-08	5.87e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—coronary artery disease	6.08e-08	4.79e-07	CbGpPWpGaD
